



June 6, 2022

Web Announcement 2795

Drug Use Review (DUR) Board Approves Changes Effective June 6, 2022

The Nevada Medicaid Drug Use Review (DUR) Board met on January 27, 2022, and voted to adopt the following changes effective June 6, 2022:

Drug Class/Program	Changes
Antiretrovirals	Added new prior authorization criteria for Cabenuva®.
Calcitonin Gene-Related Peptide (CGRP) Receptor Inhibitor Agents	Updated prior authorization to include Qulipta®.
Cystic Fibrosis	Updated prior authorization criteria for age indications.
Duchenne Muscular Dystrophy	Added new prior authorization criteria for Amondys 45®.
Immunomodulators	Updated prior authorization to include Zeposia®.
Monoclonal Antibodies for the Treatment of Respiratory Conditions	Updated prior authorization criteria for Dupixent® and Fasenna®.
Neuropathic Pain and Fibromyalgia	Updated prior authorization for Qutenza®.
Topical Immunomodulators	Added new prior authorization criteria for Opzelura®.

Prior authorization forms may be found on the Pharmacy Forms webpage at:

<https://www.medicaid.nv.gov/providers/rx/rxforms.aspx>